Development of an in vitro mRNA degradation assay utilizing extracts from HIV-1- and SIV-infected cells - PubMed (original) (raw)
. 1996 Mar 1;217(1):158-66.
doi: 10.1006/viro.1996.0103.
Affiliations
- PMID: 8599200
- DOI: 10.1006/viro.1996.0103
Free article
Development of an in vitro mRNA degradation assay utilizing extracts from HIV-1- and SIV-infected cells
M B Agy et al. Virology. 1996.
Free article
Abstract
We previously demonstrated that cellular mRNAs are degraded in CD4 positive lymphocytes infected by the human immunodeficiency virus, HIV-1, but not in cells infected by the simian lentivirus, SIV. To begin to define the molecular mechanisms underlying this RNA degradation, we have established an in vitro RNA degradation assay utilizing extracts from both infected and uninfected cells. We found that in vitro transcribed, 32P-radiolabeled actin RNA was degraded in extracts prepared from CEM, CEMx174, and C8166 cells which were infected with HIV-1. Minimal actin RNA degradation was observed in extracts prepared from uninfected cells. Similarly little degradation was observed in cell-free extracts prepared from SIV-infected cells. To determine if viral RNA sequences could impart enhanced stability to cellular RNAs in our in vitro assay, we prepared radiolabeled RNAs that contained selected viral RNA determinants. One such RNA contained the HIV-1 specific TAR (transactivating region) sequence (nucleotides 1-111) appended to a reporter CAT RNA. Like the cellular actin RNA, these TARCAT RNAs were degraded in HIV-1-infected cell extracts, but not in extracts from uninfected cells or extracts prepared from SIV-infected cells. In contrast, an RNA containing only authentic HIV-1 sequences comprising TAR and gag sequences was more stable than actin RNA in HIV-1-infected extracts. These results, taken together, suggest that the in vitro assay reproduces events that occur in vivo and provide a starting point for identifying the factor responsible for cellular RNA degradation in HIV-1-infected cells.
Similar articles
- Interferon inhibits the replication of HIV-1, SIV, and SHIV chimeric viruses by distinct mechanisms.
Korth MJ, Taylor MD, Katze MG. Korth MJ, et al. Virology. 1998 Aug 1;247(2):265-73. doi: 10.1006/viro.1998.9249. Virology. 1998. PMID: 9705919 - Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
Kaiser P, Joos B, Niederöst B, Weber R, Günthard HF, Fischer M. Kaiser P, et al. J Virol. 2007 Sep;81(18):9693-706. doi: 10.1128/JVI.00492-07. Epub 2007 Jul 3. J Virol. 2007. PMID: 17609262 Free PMC article. Clinical Trial. - Regulation of viral and cellular RNA turnover in cells infected by eukaryotic viruses including HIV-1.
Katze MG, Agy MB. Katze MG, et al. Enzyme. 1990;44(1-4):332-46. doi: 10.1159/000468769. Enzyme. 1990. PMID: 1724218 Review.
Cited by
- The Drosophila RNA-binding protein HOW controls the stability of dgrasp mRNA in the follicular epithelium.
Giuliani G, Giuliani F, Volk T, Rabouille C. Giuliani G, et al. Nucleic Acids Res. 2014 Feb;42(3):1970-86. doi: 10.1093/nar/gkt1118. Epub 2013 Nov 11. Nucleic Acids Res. 2014. PMID: 24217913 Free PMC article. - Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site.
Heise T, Guidotti LG, Chisari FV. Heise T, et al. J Virol. 2001 Aug;75(15):6874-83. doi: 10.1128/JVI.75.15.6874-6883.2001. J Virol. 2001. PMID: 11435567 Free PMC article. - Exon 1 leader sequences downstream of U5 are important for efficient human immunodeficiency virus type 1 gene expression.
Lenz C, Scheid A, Schaal H. Lenz C, et al. J Virol. 1997 Apr;71(4):2757-64. doi: 10.1128/JVI.71.4.2757-2764.1997. J Virol. 1997. PMID: 9060629 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous